Zacks Research Boosts Earnings Estimates for Teladoc Health

Teladoc Health logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Zacks Research raised its FY2026 EPS forecast for Teladoc Health to a loss of $0.87 per share from $0.89, while projecting a $0.91-per-share loss for FY2027.
  • Analyst sentiment remains mixed: MarketBeat reports a consensus Hold rating and an $8.60 average price target, with five Buy, eleven Hold, and two Sell ratings.
  • Teladoc’s latest quarter beat estimates, reporting a loss of $0.15 per share versus the expected $0.22 loss and revenue of $605.1 million versus $588.1 million expected; revenue nevertheless fell 3.4% year over year.
  • MarketBeat previews top five stocks to own in December.

Teladoc Health, Inc. (NYSE:TDOC - Free Report) - Equities researchers at Zacks Research raised their FY2026 earnings per share estimates for shares of Teladoc Health in a research note issued on Wednesday, November 18th. Zacks Research analyst Team now forecasts that the health services provider will post earnings of ($0.87) per share for the year, up from their previous forecast of ($0.89). The consensus estimate for Teladoc Health's current full-year earnings is ($0.86) per share. Zacks Research also issued estimates for Teladoc Health's Q4 2026 earnings at ($0.15) EPS, Q1 2027 earnings at ($0.25) EPS, Q2 2027 earnings at ($0.23) EPS, Q3 2027 earnings at ($0.17) EPS, Q4 2027 earnings at ($0.25) EPS, FY2027 earnings at ($0.91) EPS, Q1 2028 earnings at ($0.17) EPS, Q3 2028 earnings at ($0.12) EPS and FY2028 earnings at ($0.64) EPS.

TDOC has been the subject of several other reports. Bank of America increased their price objective on Teladoc Health from $10.50 to $11.50 in a report on Thursday, October 29th. Weiss Ratings restated a "sell (d-)" rating on shares of Teladoc Health in a research note on Tuesday. Needham & Company LLC reaffirmed a "hold" rating on shares of Teladoc Health in a research report on Thursday, October 29th. Oppenheimer raised their price target on Teladoc Health from $7.00 to $10.00 and gave the stock an "outperform" rating in a research note on Monday, November 2nd. Finally, UBS Group lifted their price target on Teladoc Health from $6.50 to $9.00 and gave the company a "neutral" rating in a report on Monday, November 2nd. Five equities research analysts have rated the stock with a Buy rating, eleven have given a Hold rating and two have given a Sell rating to the company's stock. According to data from MarketBeat, the stock presently has a consensus rating of "Hold" and a consensus target price of $8.60.

View Our Latest Stock Analysis on Teladoc Health

Teladoc Health Stock Down 3.2%

TDOC stock opened at $7.80 on Friday. The company has a 50 day moving average of $6.93 and a two-hundred day moving average of $6.66. Teladoc Health has a 12-month low of $4.40 and a 12-month high of $9.89. The company has a market cap of $1.42 billion, a price-to-earnings ratio of -9.08 and a beta of 2.00.

Teladoc Health (NYSE:TDOC - Get Free Report) last posted its quarterly earnings results on Wednesday, October 28th. The health services provider reported ($0.15) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.22) by $0.07. The business had revenue of $605.10 million during the quarter, compared to analyst estimates of $588.14 million. Teladoc Health had a negative net margin of 6.27% and a negative return on equity of 11.63%. The firm's revenue was down 3.4% compared to the same quarter last year. During the same period in the prior year, the firm earned ($0.28) earnings per share.

Insider Buying and Selling

In other news, CEO Charles III sold 17,805 shares of the company's stock in a transaction that occurred on Friday, September 11th. The stock was sold at an average price of $6.10, for a total transaction of $108,610.50. Following the completion of the transaction, the chief executive officer directly owned 465,535 shares in the company, valued at $2,839,763.50. The trade was a 3.68% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Carlos Nueno sold 29,432 shares of the business's stock in a transaction on Friday, November 6th. The stock was sold at an average price of $9.20, for a total transaction of $270,774.40. Following the transaction, the insider directly owned 35,312 shares in the company, valued at $324,870.40. This trade represents a 45.46% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 47,892 shares of company stock worth $383,086 in the last ninety days. Insiders own 0.70% of the company's stock.

Institutional Trading of Teladoc Health

A number of hedge funds have recently modified their holdings of the company. Monaco Asset Management SAM acquired a new stake in Teladoc Health during the second quarter worth $26,864,000. Counterpoint Mutual Funds LLC raised its position in Teladoc Health by 1,017.4% in the third quarter. Counterpoint Mutual Funds LLC now owns 1,650,165 shares of the health services provider's stock worth $9,571,000 after purchasing an additional 1,502,488 shares in the last quarter. Quantinno Capital Management LP raised its holdings in shares of Teladoc Health by 128.0% in the 1st quarter. Quantinno Capital Management LP now owns 2,621,378 shares of the health services provider's stock worth $14,287,000 after buying an additional 1,471,631 shares in the last quarter. Pale Fire Capital SE boosted its stake in Teladoc Health by 74.8% in the 1st quarter. Pale Fire Capital SE now owns 3,398,491 shares of the health services provider's stock valued at $18,522,000 after buying an additional 1,454,288 shares in the last quarter. Finally, Freestone Grove Partners LP bought a new stake in Teladoc Health in the second quarter valued at $7,338,000. Institutional investors own 76.82% of the company's stock.

Recent Teladoc Health Headlines

Here are a few of the latest headlines about TDOC:

  • Positive Sentiment: Zacks raised its FY2026 EPS estimate to a loss of $0.87 from $0.89 and its FY2027 estimate to a loss of $0.91 from $0.98. It also improved several quarterly forecasts, including Q3 2027, from a loss of $0.26 to $0.17 per share. Teladoc Health analyst estimates
  • Neutral Sentiment: Truist raised its price target to $9 from $8 but maintained a Hold rating, signaling a higher valuation view without a change to its recommendation. Truist price-target update
  • Negative Sentiment: Zacks lowered estimates for Q4 2026, Q4 2027, Q1 2028, and FY2028. Its revised FY2028 forecast is a loss of $0.64 per share, compared with $0.63 previously. These cuts temper the positive revisions and keep the overall outlook mixed. Teladoc Health analyst estimates

Teladoc Health Company Profile

(Get Free Report)

Teladoc Health, Inc. provides virtual healthcare services through a digital platform that connects individuals with clinicians and other health professionals. Its offerings include virtual primary and specialty care, mental health services, and support for managing chronic conditions. The company serves members in the United States and internationally, with services and availability varying by market. Its consumer mental health services include BetterHelp, while its chronic-care programs draw on technology and services developed by Livongo, which Teladoc acquired in 2020.

Featured Articles

Earnings History and Estimates for Teladoc Health (NYSE:TDOC)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Teladoc Health Right Now?

Before you consider Teladoc Health, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Teladoc Health wasn't on the list.

While Teladoc Health currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines